Drug Interactions for Patients with Respiratory Diseases Receiving COVID-19 Emerged Treatments
Pandemic of coronavirus disease (COVID-19) is still pressing the healthcare systems worldwide. Thus far, the lack of available COVID-19-targeted treatments has led scientists to look through drug repositioning practices and exploitation of available scientific evidence for potential efficient drugs...
Enregistré dans:
Auteurs principaux: | Marios Spanakis, Athina Patelarou, Evridiki Patelarou, Nikolaos Tzanakis |
---|---|
Format: | article |
Langue: | EN |
Publié: |
MDPI AG
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/c8e11f03c1724e42be50bdc78ade76c4 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
COVID-19 Vaccine Hesitancy in Healthcare Personnel: A University Hospital Experience
par: Beril Kara Esen, et autres
Publié: (2021) -
Predicting adverse drug reactions in older adults; a systematic review of the risk prediction models
par: Stevenson JM, et autres
Publié: (2014) -
The war on COVID-19 and vaccination mandates: Ethical code of conduct
par: Norma Visagie
Publié: (2021) -
Mechanisms and the clinical relevance of complex drug–drug interactions
par: Roberts AG, et autres
Publié: (2018) -
Workforce
Publié: (1997)